Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2025-04-29 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a repurchase and cancellation of restricted shares under a stock incentive plan. It details the number of shares repurchased, the price, the approval process, and the impact on the company's share capital. It is not a full financial report, earnings release, or management discussion. It is a specific corporate action related to share repurchase and cancellation of shares. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2025-04-29 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '安徽安科生物工程(集团)股份有限公司2025 年第一季度报告' which translates to 'Anhui Anke Biological Engineering (Group) Co., Ltd. 2025 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the first quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It is not an announcement or a brief summary but a full report with substantive financial data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-28 Chinese
关于参股公司获得药物临床试验默示许可的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding a clinical trial implicit approval for a drug developed by its associated companies. It details the drug name, applicant names, indication, and regulatory approval status from the National Medical Products Administration's Center for Drug Evaluation (CDE). The document includes a risk warning about the clinical trial process and investment risks. It is a regulatory announcement about a clinical trial approval, not a financial report, earnings release, or management discussion. The document is short (878 characters) and serves as a formal notification to investors about a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-04-24 Chinese
2024年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a "2024年度股东大会决议公告" which translates to "2024 Annual General Meeting Resolution Announcement." It details the resolutions passed at the 2024 Annual General Meeting (AGM) of the company, including voting results on various proposals such as the 2024 board work report, financial report, profit distribution plan, auditor appointment, and other governance matters. The document includes attendance details, voting percentages, and legal opinions confirming the validity of the meeting and resolutions. There is no full financial report or detailed financial statements included, only the announcement of the AGM resolutions and voting outcomes. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" which covers official results from shareholder votes at any general meeting. The document length is sufficient and contains substantive voting results, not just a brief notice or a report publication announcement. Therefore, the correct classification is DVA.
2025-04-18 Chinese
安徽天禾律师事务所关于安徽安科生物工程（集团）股份有限公司2024年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2024 Annual General Meeting (AGM) of Anhui Anke Bioengineering (Group) Co., Ltd. It details the legality of the AGM's convening, attendance, voting procedures, and results. The document includes detailed voting results on various proposals discussed at the AGM. It does not contain financial statements or management discussion but focuses on the legal compliance and validity of the AGM process and resolutions. This type of document is typically associated with the AGM Information category, as it provides materials related to the Annual General Meeting rather than the full annual report or other filings.
2025-04-18 Chinese
关于召开2024年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2024 annual performance explanation meeting (业绩说明会) to be held online on April 10, 2025. It references that the company's 2024 annual report and its summary have already been disclosed on March 28, 2025. The document invites investors to participate in the online meeting and submit questions. The content is primarily an invitation and notice for an investor presentation event rather than the presentation materials themselves or the full annual report. The document length is short (743 characters), and it does not contain financial data or detailed analysis but rather logistical information about the upcoming event. Therefore, it fits best as an Investor Presentation (IP) announcement or notice. Given the nature of the document as a notice for an investor meeting focused on financial results and company performance, the classification is Investor Presentation (IP).
2025-04-07 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.